Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887929 | 0.83 | ALDH1A1 (0.43) | KDM4ELMNAMAPTCYP19A1ALDH1A1 | |
| SCHEMBL1144412 | 0.82 | ALDH1A1 (0.51) | KCNA5CYP3A4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL167043 | 0.82 | ALDH1A1 (0.51) | KCNA5CYP3A4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL476790 | 0.82 | ALDH1A1 (0.51) | KCNA5CYP3A4CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL28275305 | 0.82 | LMNA (0.38) | KCNA5CYP2D6LMNADPP4CYP19A1 | |
| SCHEMBL28274163 | 0.82 | LMNA (0.38) | KCNA5CYP2D6LMNADPP4CYP19A1 | |
| SCHEMBL6954924 | 0.81 | KCNA5 (0.56) | KCNA5KDM4ELMNAALDH1A1 | |
| SCHEMBL2298713 | 0.81 | KCNA5 (0.56) | KCNA5KDM4ELMNAALDH1A1 | |
| SCHEMBL5720902 | 0.81 | CYP19A1 (0.42) | CYP3A4CYP2C19KDM4ECYP1A2CYP2D6 | |
| SCHEMBL5929596 | 0.81 | KCNA5 (0.49) | KCNA5CYP3A4CYP2C19MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2083011-B1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2014-06-04 | — | — | EP | disclosed |
| CN-101186612-B | Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application | TIANJIN HEMEI BIOLOG TECHNOLOGY CO LTD | 2012-10-03 | — | — | CN | disclosed |
| EP-2083011-A1 | PYRROLINE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-07-29 | — | — | EP | disclosed |
| CN-101186612-A | Pyrroline derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application | TIANJIN HEMEI BIOLOG TECHNOLOG (CN) | 2008-05-28 | — | — | CN | disclosed |
| US-7312230-B2 | Carboxylic acid derivatives as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7056903-B2 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | COURNOYER RICHARD L | 2006-02-16 | — | — | US | disclosed |
| EP-1102766-B1 | TRIAZOLOPYRIDINES FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| CN-1320125-A | Trizolopyridines for the treamtent of thrombosis disorders | ORTHO MCNEIL PHARM INC (US) | 2001-10-31 | — | — | CN | disclosed |
| US-6303625-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS WHICH INHIBIT PLATELET AGGREGATION AND ARE USEFUL IN TREATING THROMBOTIC DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-16 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
| EP-1102766-A1 | TRIAZOLOPYRIDINES FOR THE TREATMENT OF THROMBOSIS DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000006570-A1 | TRIAZOLOPYRIDINES FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | AGTR1, AGTR2, PTGIR | KCNA5 227/4885CYP3A4 585/4885CYP2C19 785/4885 |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | KCNA5 650/4885CYP3A4 780/4885CYP2C19 1090/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | KCNA5 692/4885CYP3A4 735/4885CYP2C19 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.